RSI Oversold Stocks
NMRA is flagged as RSI oversold, meaning recent selling pressure has pushed momentum to extreme levels that may lead to a short-term rebound.
NEUMORA THERAPEUTICS INC (NMRA) Stock Price & Overview
NASDAQ:NMRA • US6409791000
Current stock price
1.98 USD
+0.03 (+1.54%)
Last:
The current stock price of NMRA is 1.98 USD. Today NMRA is up by 1.54%. In the past month the price decreased by -36.27%. In the past year, price increased by 164.77%.
NMRA Key Statistics
52-Week Range0.611 - 3.65
Current NMRA stock price positioned within its 52-week range.
1-Month Range1.82 - 3.52
Current NMRA stock price positioned within its 1-month range.
- Market Cap
- 326.284M
- P/E
- N/A
- Fwd P/E
- N/A
- EPS (TTM)
- -1.42
- Dividend Yield
- N/A
NMRA Stock Performance
Today
+1.54%
1 Week
-21.05%
1 Month
-36.27%
3 Months
+17.47%
Longer-term
6 Months +6.56%
1 Year +164.77%
2 Years -85.82%
3 Years N/A
5 Years N/A
10 Years N/A
NMRA Stock Chart
NMRA Stock Screens
NMRA currently appears in the following ChartMill screener lists.
NMRA Technical Analysis
ChartMill assigns a technical rating of 3 / 10 to NMRA. When comparing the yearly performance of all stocks, NMRA is one of the better performing stocks in the market, outperforming 95.37% of all stocks.
Chartmill TA Rating
Chartmill Setup Rating
NMRA Fundamental Analysis
ChartMill assigns a fundamental rating of 1 / 10 to NMRA. The financial health of NMRA is average, but there are quite some concerns on its profitability.
Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend
NMRA Earnings
Next Earnings DateMay 6, 2026
Last Earnings DateMar 30, 2026
PeriodQ4 / 2025
EPS Reported-$0.35
Revenue Reported
EPS Surprise -5.40%
Revenue Surprise %
NMRA Forecast & Estimates
15 analysts have analysed NMRA and the average price target is 7.82 USD. This implies a price increase of 294.95% is expected in the next year compared to the current price of 1.98.
Analysts
Analysts81.33
Price Target7.82 (294.95%)
EPS Next Y25.74%
Revenue Next YearN/A
NMRA Groups
Sector & Classification
NMRA Financial Highlights
Over the last trailing twelve months NMRA reported a non-GAAP Earnings per Share(EPS) of -1.42. The EPS increased by 7.19% compared to the year before.
Income Statements
Revenue(TTM)N/A
Net Income(TTM)-236.30M
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -132.88% | ||
| ROE | -178.79% | ||
| Debt/Equity | 0.15 |
Chartmill High Growth Momentum
EPS Q2Q%5.41%
Sales Q2Q%N/A
EPS 1Y (TTM)7.19%
Revenue 1Y (TTM)N/A
NMRA Ownership
Ownership
Inst Owners62.23%
Shares164.79M
Float120.67M
Ins Owners5.31%
Short Float %4.11%
Short Ratio4.03
NMRA Competitors/Peers
The largest stocks on the US markets in the "Pharmaceuticals" sub-industry
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 27.42 | 867.674B | ||
| JNJ | JOHNSON & JOHNSON | 20.95 | 588.761B | ||
| MRK | MERCK & CO. INC. | 23.41 | 297.404B | ||
| PFE | PFIZER INC | 9.57 | 159.729B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 9.76 | 123.512B | ||
| ZTS | ZOETIS INC | 16.59 | 49.9B | ||
| RPRX | ROYALTY PHARMA PLC- CL A | 9.4 | 27.672B | ||
| VTRS | VIATRIS INC | 5.42 | 15.555B | ||
| ELAN | ELANCO ANIMAL HEALTH INC | 22.16 | 11.897B | ||
| AXSM | AXSOME THERAPEUTICS INC | N/A | 8.645B | ||
| BLTE | BELITE BIO INC - ADR | N/A | 5.981B | ||
| TERN | TERNS PHARMACEUTICALS INC | N/A | 5.599B | ||
| CORT | CORCEPT THERAPEUTICS INC | 51.38 | 4.288B |
Related stock screener links
View all stocks in the Pharmaceuticals Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About NMRA
Company Profile
Neumora Therapeutics, Inc. is a clinical-stage biotechnology company. The company is headquartered in Watertown, Massachusetts and currently employs 95 full-time employees. The company went IPO on 2023-09-15. The firm's therapeutic pipeline consists of seven clinical and preclinical neuroscience programs that target novel mechanisms of action for a broad range of underserved neuropsychiatric disorders and neurodegenerative diseases. Its advanced product candidate, navacaprant (NMRA-140), is a novel once-daily oral kappa opioid receptor (KOR) antagonist that is being developed for the treatment of depressive disorder (MDD). Navacaprant is being investigated in the KOASTAL pivotal Phase 3 program, evaluating navacaprant monotherapy in patients with moderate to severe MDD. The firm's next advanced product candidate is NMRA-511, which is a highly selective, novel antagonist of the vasopressin 1a receptor (V1aR) being developed for the treatment of agitation associated with dementia due to Alzheimer's disease (AD).
Company Info
IPO: 2023-09-15
NEUMORA THERAPEUTICS INC
260 Arsenal Place, Suite 1
Watertown MASSACHUSETTS US
Employees: 95
Phone: 18577600900
NEUMORA THERAPEUTICS INC / NMRA FAQ
What does NMRA do?
Neumora Therapeutics, Inc. is a clinical-stage biotechnology company. The company is headquartered in Watertown, Massachusetts and currently employs 95 full-time employees. The company went IPO on 2023-09-15. The firm's therapeutic pipeline consists of seven clinical and preclinical neuroscience programs that target novel mechanisms of action for a broad range of underserved neuropsychiatric disorders and neurodegenerative diseases. Its advanced product candidate, navacaprant (NMRA-140), is a novel once-daily oral kappa opioid receptor (KOR) antagonist that is being developed for the treatment of depressive disorder (MDD). Navacaprant is being investigated in the KOASTAL pivotal Phase 3 program, evaluating navacaprant monotherapy in patients with moderate to severe MDD. The firm's next advanced product candidate is NMRA-511, which is a highly selective, novel antagonist of the vasopressin 1a receptor (V1aR) being developed for the treatment of agitation associated with dementia due to Alzheimer's disease (AD).
Can you provide the latest stock price for NEUMORA THERAPEUTICS INC?
The current stock price of NMRA is 1.98 USD. The price increased by 1.54% in the last trading session.
Does NMRA stock pay dividends?
NMRA does not pay a dividend.
What is the ChartMill rating of NEUMORA THERAPEUTICS INC stock?
NMRA has a ChartMill Technical rating of 3 out of 10 and a ChartMill Fundamental rating of 1 out of 10.
Can you provide the upcoming earnings date for NEUMORA THERAPEUTICS INC?
NEUMORA THERAPEUTICS INC (NMRA) will report earnings on 2026-05-06.